

SENATE SUMMARY OF HOUSE AMENDMENTS

SB 253

2026 Regular Session

McMath

KEYWORD AND SUMMARY AS RETURNED TO THE SENATE

PUBLIC HEALTH. Provides for peptides. (8/1/26)

SUMMARY OF HOUSE AMENDMENTS TO THE SENATE BILL

1. Remove the provision that prescribing providers ensure that any peptides prescribed are prepared in accordance with FDA or United States Code regulations.
2. Make technical changes.

DIGEST OF THE SENATE BILL AS RETURNED TO THE SENATE

DIGEST

SB 253 Reengrossed

2026 Regular Session

McMath

Proposed law provides that no professional or occupational licensing board shall prohibit a healthcare provider with prescriptive authority from providing patients with peptides shipped from either of the following:

- (1) A FDA-registered 503B outsourcing facility that is in compliance with 21 U.S.C. 353b.
- (2) A 503A compounding pharmacy that is in compliance with 21 U.S.C. 353a and applicable United States Pharmacopeia - National Formulary chapters.

Proposed law provides that no professional or occupational licensing board shall prohibit a La. licensed pharmacist in a state permitted pharmacy from compounding and dispensing peptides as long as the pharmacist and pharmacy are in compliance with 21 U.S.C. 353a and applicable United States Pharmacopeia - National Formulary chapters.

Effective August 1, 2026.

(Adds R.S. 37:23.5)

Thomas L. Tyler
Senate Counsel